Home / Market News / $LGND

$LGND news and market catalysts

The 15 most recent market catalysts affecting $LGND, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 0 high impact 9 bullish 0 bearish Biotechnology
Nov 4, 2026 Corporate Catalyst Neutral Impact 55
Ligand Pharmaceuticals Insider Executes Stock Sale
A Ligand Pharmaceuticals insider executed a stock sale totaling $1,566,094, as reported in an SEC filing on November 4, 2026. This event matters as insider selling can sometimes be…
Oct 30, 2026 Corporate Catalyst Neutral Impact 55
Ligand Pharmaceuticals Participates in Pelthos Therapeutics PIPE Financing
Ligand Pharmaceuticals is participating as a PIPE investor in a private placement for Pelthos Therapeutics. This financing is directly tied to Pelthos's merger with Castle Creek Bi…
Oct 30, 2026 Corporate Catalyst Bullish Impact 65
RBC Raises Price Target on Ligand Pharmaceuticals to $357 From $345
RBC Capital Markets raised its price target for Ligand Pharmaceuticals (LGND) to $357 from $345 and maintained an Outperform rating. This positive revision is a direct consequence …
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $346 From $334
Oppenheimer's decision to raise Ligand Pharmaceuticals' price target from $334 to $346, while maintaining an Outperform rating, indicates a strengthened positive outlook on the com…
Oct 29, 2026 Corporate Catalyst Bullish Impact 75
Ligand Pharmaceuticals Reports Third Quarter 2026 Financial Results
Ligand Pharmaceuticals reported its third-quarter 2026 financial results, with the key highlight being a substantial 51% year-over-year increase in royalty revenue. This growth is …
Sep 25, 2026 Corporate Catalyst Neutral Impact 65
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Barclays analyst Glen Santangelo initiated coverage on Ligand Pharmaceuticals (LGND) with an 'Overweight' rating and a price target of $345. This is a positive development for LGND…
Sep 24, 2026 Market Technicals Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterated a 'Buy' rating and maintained a $358 price target for Ligand Pharmaceuticals. This action signals continued bullish sentimen…
Sep 23, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397
Citigroup analyst Yigal Nochomovitz maintained a 'Buy' rating on Ligand Pharmaceuticals and raised the price target from $390 to $397. This action signals continued confidence from…
Aug 14, 2026 Corporate Catalyst Neutral Impact 65
Leerink Partners Initiates Coverage On Ligand Pharmaceuticals with Outperform Rating, Announces Price Target of $330
Leerink Partners, through analyst David Risinger, has initiated coverage on Ligand Pharmaceuticals (LGND) with an 'Outperform' rating and a price target of $330. This event is sign…
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $345
RBC Capital's analyst Douglas Miehm maintained an 'Outperform' rating for Ligand Pharmaceuticals and slightly increased the price target from $340 to $345. This action signals ongo…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $358
HC Wainwright & Co. analyst Joseph Pantginis maintained a 'Buy' rating on Ligand Pharmaceuticals and raised the price target from $289 to $358. This upward revision in the price ta…
Aug 6, 2026 Corporate Catalyst Bullish Impact 75
Ligand Pharmaceuticals Q2 Adj. EPS $2.37 Beats $1.84 Estimate, Sales $63.693M Beat $60.765M Estimate
This headline is a significant corporate catalyst for Ligand Pharmaceuticals. Beating both EPS and sales estimates by a considerable margin suggests strong underlying business fund…
Aug 3, 2026 Corporate Catalyst Bullish Impact 65
Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326
Oppenheimer analyst Leland Gershell reiterated an 'Outperform' rating for Ligand Pharmaceuticals and raised the price target from $285 to $326. This upgrade signals increased confi…
Jul 21, 2026 Corporate Catalyst Neutral Impact 65
Citigroup Reinstates Buy on Ligand Pharmaceuticals, Announces $387 Price Target
Citigroup's reinstatement of a 'Buy' rating and establishment of a $387 price target for Ligand Pharmaceuticals (LGND) is a positive development for the company. Analyst ratings an…
Jul 15, 2026 Corporate Catalyst Bullish Impact 65
RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $340
RBC Capital analyst Douglas Miehm reiterated an Outperform rating for Ligand Pharmaceuticals and significantly raised the price target from $262 to $340. This analyst upgrade indic…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.